Korea Price Cuts Could Trigger Reduced Big Pharma Investment
This article was originally published in PharmAsia News
Price cuts initiated in April have hurt both multinational and local companies, and rather than trigger more R&D as hoped, the policy could dampen investment in Korea.
You may also be interested in...
SEOUL - South Korea's Ministry of Health and Welfare held a two-day forum offering a rare opportunity for Korean and foreign pharmaceutical officials to offer comments on the ministry's controversial new pricing system
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.